Ambrosus, a blockchain-based supply chain ecosystem, is working with Trek Therapeutics to apply a combination of integrated sensors and blockchain-based technology to pharmaceutical drug manufacturing in Trek’s development program.
The Ambrosus ecosystem uses high-tech sensors, blockchain, and smart contracts to produce a publicly-verifiable, community-driven method of ensuring the origins, quality and safety of products such as medicine, food and commodities. Ambrosus will conduct pilot projects with Trek which monitor all stages of the pharmaceutical manufacturing process.
“Currently the pharmaceutical manufacturing process is highly regulated by pharmaceutical manufacturers and by regulatory authorities in an extremely labor-intensive and expensive manner,” Trek cofounder and CEO Dr. Ann Kwong said. “We hope to partner with Ambrosus to create a continuous monitoring and tracking system that will be less labor intensive, less expensive, and more transparent to all parties with a stake in quality pharmaceutical manufacturing.
“Our goal is to develop a system that is robust enough that Trek can submit data to support our manufacturing application for regulatory approval of our drugs from the FDA and EMA authorities.”
Dr. Kwong added the system will show patients that Trek’s products are both affordable and of the highest quality.
“Following the successful implementation of the Ambrosus protocol in global food supply chains, we are delighted to now apply our blockchain protocol to help ensure the quality, safety and integrity of another vitally important product – pharmaceuticals,” Ambrosus cofounder and CEO Angel Versetti said.
Trek Therapeutics is a privately held, public benefit corporation developing treatments for serious infections. It aims to provide cost-effective, affordable and accessible medicines to treat patients suffering from infectious diseases before commercializing them for global populations. Since being founded in 2014, Trek has completed a $10 million Series A round and recruited managers and board members from Vertex, Schering Plough/Merck, Pharmasset/Gilead, Bristol-Myers Squibb, Roche, Celgene Global Health, Idenix, and Genzyme.
“Trek is focused on developing safe, novel medicines for infectious diseases at affordable and accessible prices,” Mr. Versetti said. “The pharmaceutical supply chain encompasses many phases and a multitude of stakeholders, requiring responsible parties to seek new methods of guaranteeing the quality and integrity of critical products. As Trek continues their mission to develop pharmaceuticals for budget-constrained patients across North America and Europe, our partnership will help to develop protocols to provide transparency and quality assurance during each phase of the process.”
During the pilots the Ambrosus protocol will work to verify and track the entire manufacturing chain from the chemical ingredients through synthesis, purification and verification of the active pharmaceutical ingredient and on to the packaging, labeling, storage and shipping to clinical trial sites.
“Backed by a superb core team of developers, advisors, and researchers, Ambrosus’ protocol will provide the transparency necessary in our manufacturing process to help ensure the integrity of supply chains,” Dr. Kwong said. “With our commitment to providing affordable high quality medicine, we believe this partnership could revolutionize the pharmaceutical industry quality control of manufacturing at every stage from plant to patient.”
Jaron Lukasiewicz is now advising Ambrosus. The founder and former CEO of Coinsetter, Mr. Lukasiewicz was also CEO of Canada’s oldest and largest bitcoin exchange Cavirtex. He is currently the CEO of WORKFLOW.
“I am excited about the future of the Ambrosus project and equally the team behind it, who together carries decades of experience in their target markets,” Mr. Lukasiewicz said. “Ambrosus can become a fundamental technology utilized in sectors ranging from food to pharma, stretching the boundaries of what blockchain technology can accomplish in real world applications.”